Gene · 5499
Papers4,146
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 4,146
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Allosteric regulation and crystallographic fragment screening of SARS-CoV-2 NSP15 endoribonuclease. | Nucleic Acids Res | 2023 | 37115000 | PubTator, text mining | PubMed |
| Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism. | Emerg Microbes Infect | 2023 | 37114433 | PubTator, text mining | PubMed |
| Editorial: The role of mortalin in biology and disease. | Front Cell Dev Biol | 2023 | 37113770 | PubTator, text mining | PubMed |
| Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. | Viruses | 2023 | 37112923 | PubTator, text mining | PubMed |
| Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. | Viruses | 2023 | 37112871 | PubTator, text mining | PubMed |
| In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. | Vaccines (Basel) | 2023 | 37112648 | PubTator, text mining | PubMed |
| Design of Potent Inhibitors Targeting the Main Protease of SARS-CoV-2 Using QSAR Modeling, Molecular Docking, and Molecular Dynamics Simulations. | Pharmaceuticals (Basel) | 2023 | 37111365 | PubTator, text mining | PubMed |
| Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. | Microorganisms | 2023 | 37110423 | PubTator, text mining | PubMed |
| Severe COVID-19: Drugs and Clinical Trials. | J Clin Med | 2023 | 37109231 | PubTator, text mining | PubMed |
| The functional and evolutionary impacts of human-specific deletions in conserved elements. | Science | 2023 | 37104592 | PubTator, text mining | PubMed |
| Large-scale phage-based screening reveals extensive pan-viral mimicry of host short linear motifs. | Nat Commun | 2023 | 37100772 | PubTator, text mining | PubMed |
| Reticulons promote formation of ER-derived double-membrane vesicles that facilitate SARS-CoV-2 replication. | J Cell Biol | 2023 | 37093123 | PubTator, text mining | PubMed |
| Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies. | J Enzyme Inhib Med Chem | 2023 | 37092260 | PubTator, text mining | PubMed |
| PP1γ regulates neuronal insulin signaling and aggravates insulin resistance leading to AD-like phenotypes. | Cell Commun Signal | 2023 | 37085815 | PubTator, text mining | PubMed |
| Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. | Eur J Clin Pharmacol | 2023 | 37081137 | PubTator, text mining | PubMed |
Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). | Eur J Med Chem | 2023 | 37080108 | PubTator, text mining | PubMed |
| Therapeutic strategies for COVID-19: progress and lessons learned. | Nat Rev Drug Discov | 2023 | 37076602 | PubTator, text mining | PubMed |
| Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. | Antiviral Res | 2023 | 37076089 | PubTator, text mining | PubMed |
| Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection. | mBio | 2023 | 37074178 | PubTator, text mining | PubMed |
| FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms. | Biomed Pharmacother | 2023 | 37068330 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5499/papers?page=16